Carabrone Attenuates Metabolic Dysfunction–Associated Steatohepatitis by Targeting STAT3 in Mice

Abstract

Metabolic dysfunction–associated steatohepatitis (MASH) has become one of the most common progressive liver diseases worldwide, but effective treatment options are severely unmet. Carabrone, a sesquiterpene lactone from the traditional Chinese herb Carpesium abrotanoides L., shows various pharmacological properties, whereas its effect on the improvement of MASH and the underlying mechanisms have not yet been reported. In this work, we revealed for the first time the beneficial effect of carabrone on MASH, including reducing liver lipid accumulation, inflammatory cell infiltration, and fibrosis in multiple diet-induced mice. Carabrone also alleviated lipid accumulation and inflammation in palmitic acid/oleic acid–stimulated hepatocytes. Mechanically, we identified signal transducers and transcriptional activator 3 (STAT3) as a key target of carabrone for treating MASH through quantitative chemical proteomic analysis, as well as the verification by the overexpression of STAT3 in vivo and in vitro. Further studies demonstrated that carabrone blocks MASH progression by inhibiting the activation of STAT3. More importantly, a new carabrone derivative CA-21 with stronger anti-MASH activity and affinity for STAT3 was discovered through rational structural modification. Taken together, our findings suggest that carabrone and CA-21 could be developed as promising drug candidates for MASH treatment.

Keywords

carabrone / chemoproteomic profiling / MASH / STAT3

References

[1] D. E. Kleiner, E. M. Brunt, M. Van Natta, et al., “Design and Validation of a Histological Scoring System for Nonalcoholic Fatty Liver Disease,” Hepatology 41 (2005): 1313–1321.

[2] C. Estes, H. Razavi, R. Loomba, et al., “Modeling the Epidemic of Nonalcoholic Fatty Liver Disease Demonstrates an Exponential Increase in Burden of Disease,” Hepatology 67 (2018): 23–33.

[3] H. Tilg, C. D. Byrne, and G. Targher, “Nash Drug Treatment Development: Challenges and Lessons,” Lancet Gastroenterology 8 (2023): 943–954.

[4] K. M. Korenblat, E. Fabbrini, B. S. Mohammed, et al., “Liver, Muscle, and Adipose Tissue Insulin Action Is Directly Related to Intrahepatic Triglyceride Content in Obese Subjects,” Gastroenterology 134 (2008): 1369–1375.

[5] M. Eslam, P. N. Newsome, S. K. Sarin, et al., “A New Definition for Metabolic Dysfunction-Associated Fatty Liver Disease: An International Expert Consensus Statement,” Journal of Hepatology 73 (2020): 202–209.

[6] G. Marchesini, C. P. Day, J. F. Dufour, et al., “EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease,” Journal of Hepatology 64 (2016): 1388–1402.

[7] S. A. Harrison, P. Bedossa, C. D. Guy, et al., “A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis,” The New England Journal of Medicine 390 (2024): 497–509.

[8] S. Petta, G. Targher, S. Romeo, et al., “The First MASH Drug Therapy on the Horizon: Current Perspectives of Resmetirom,” Liver International 44 (2024): 1526–1536.

[9] S. J. Woo, M. G. Jeong, E. J. Jeon, et al., “Antiparasitic Potential of Ethanolic Extracts of Carpesii Fructus Against Miamiensis Avidus in Hirame Natural Embryo Cell Line and Their Effects on Immune Response-and Biotransformation-Related Genes,” Comparative Biochemistry and Physiology. Toxicology & Pharmacology 251 (2022): 109214.

[10] X. Feng, H. Jiang, Y. Zhang, et al., “Insecticidal Activities of Ethanol Extracts From Thirty Chinese Medicinal Plants Against Spodoptera exigua (Lepidoptera: Noctuidae),” Journal of Medicinal Plants Research 6 (2012): 1263–1267.

[11] B. Mayur, S. Sandesh, S. Shruti, et al., “Antioxidant and α-Glucosidase Inhibitory Properties of Carpesium abrotanoides L,” Journal of Medicinal Plants Research 4 (2010): 1547–1553.

[12] H. J. Kang, H.-J. Kim, S.-I. Jeong, et al., “Antioxidant and Antihemolytic Activities of Ethanol Extracts of Carpesii Fructus and Farfarae Flos,” Korea Journal of Herbology 28 (2013): 25–31.

[13] D.-W. Jeong, E.-K. Lee, C.-H. Lee, et al., “Carpesium Abrotanoides Extract Inhibits Cyclooxygenase-2 Expression Induced by Toll-Like Receptor Agonists,” Toxicology and Environmental Health Sciences 5 (2013): 92–96.

[14] B. Shen, Y. Yang, D. Wan, et al., “Sesquiterpene Lactones Isolated From Carpesium abrotanoides L. by LC–MS Combined With HSCCC Inhibit Liver Cancer Through Suppression of the jak2/stat3 Signaling Pathway,” Medicinal Chemistry Research 31 (2022): 436–445.

[15] J. P. Zhang, G. W. Wang, X. H. Tian, et al., “The Genus Carpesium: A Review of Its Ethnopharmacology, Phytochemistry and Pharmacology,” Journal of Ethnopharmacology 163 (2015): 173–191.

[16] J. Lee, B. Min, S. Lee, et al., “Cytotoxic Sesquiterpene Lactones From Carpesium abrotanoides,” Planta Medica 68 (2002): 745–747.

[17] R. Wang, Y.-Q. Liu, W. Ha, et al., “In Vitro Anti-Inflammatory Effects of Diterpenoids and Sesquiterpenoids From Traditional Chinese Medicine Siegesbeckia pubescens,” Bioorganic & Medicinal Chemistry Letters 24 (2014): 3944–3947.

[18] A. Pan, X. M. Sun, F. Q. Huang, et al., “The Mitochondrial β-Oxidation Enzyme HADHA Restrains Hepatic Glucagon Response by Promoting β-Hydroxybutyrate Production,” Nature Communications 13, no. 1 (2022): 386.

[19] Y. Wu, Y. Yang, W. Wang, et al., “PROTAC Technology as a Novel Tool to Identify the Target of Lathyrane Diterpenoids,” Acta Pharmaceutica Sinica B 12 (2022): 4262–4265.

[20] J. Park, Y. Zhao, F. Zhang, et al., “Il-6/stat3 Axis Dictates the pnpla3-Mediated Susceptibility to Non-Alcoholic Fatty Liver Disease,” Journal of Hepatology 78 (2023): 45–56.

[21] F. Zhou, J. Zhou, W. Wang, et al., “Unexpected Rapid Increase in the Burden of NAFLD in China From 2008 to 2018: A Systematic Review and Meta-Analysis,” Hepatology 70 (2019): 1119–1133.

[22] Y. Zhu, Z. Ouyang, H. Du, et al., “New Opportunities and Challenges of Natural Products Research: When Target Identification Meets Single-Cell Multiomics,” Acta Pharmaceutica Sinica B 12, no. 11 (2022): 4011–4039.

[23] N. Worm, “Beyond Body Weight-Loss: Dietary Strategies Targeting Intrahepatic Fat in NAFLD,” Nutrients 12 (2020): 1316.

[24] B. Gao, H. Wang, F. Lafdil, et al., “Stat Proteins—Key Regulators of Anti-Viral Responses, Inflammation, and Tumorigenesis in the Liver,” Journal of Hepatology 57 (2012): 430–441.

[25] Z. Li, P.-P. Feng, Z.-B. Zhao, et al., “Liraglutide Protects Against Inflammatory Stress in Non-Alcoholic Fatty Liver by Modulating Kupffer Cells m2 Polarization via Camp-pka-stat3 Signaling Pathway,” Biochemical and Biophysical Research Communications 510 (2019): 20–26.

[26] J. Zhu, M. Zhou, X. Zhao, et al., “Blueberry, Combined With Probiotics, Alleviates Non-Alcoholic Fatty Liver Disease via Il-22-Mediated jak1/stat3/Bax Signaling,” Food & Function 9 (2018): 6298–6306.

[27] J. Zhu, T. Ren, M. Zhou, et al., “The Combination of Blueberry Juice and Probiotics Reduces Apoptosis of Alcoholic Fatty Liver of Mice by Affecting sirt1 Pathway,” Drug Design, Development and Therapy 10 (2016): 1649–1661.

[28] H. Y. Seo, M. K. Kim, S. H. Lee, et al., “Kahweol Ameliorates the Liver Inflammation Through the Inhibition of NF-κB and STAT3 Activation in Primary Kupffer Cells and Primary Hepatocytes,” Nutrients 10 (2018): 863.

[29] H. Inoue, W. Ogawa, M. Ozaki, et al., “Role of STAT-3 in Regulation of Hepatic Gluconeogenic Genes and Carbohydrate Metabolism in Vivo,” Nature Medicine 10 (2004): 168–174.

[30] A. M. Miller, H. Wang, A. Bertola, et al., “Inflammation-Associated Interleukin-6/Signal Transducer and Activator of Transcription 3 Activation Ameliorates Alcoholic and Nonalcoholic Fatty Liver Diseases in Interleukin-10-Deficient Mice,” Hepatology 54 (2011): 846–856.

[31] S. H. Ki, O. Park, M. Zheng, et al., “Interleukin-22 Treatment Ameliorates Alcoholic Liver Injury in a Murine Model of Chronic-Binge Ethanol Feeding: Role of Signal Transducer and Activator of Transcription 3,” Hepatology 52 (2010): 1291–1300.

[32] L. Yang, Y. Zhang, L. Wang, et al., “Amelioration of High Fat Diet Induced Liver Lipogenesis and Hepatic Steatosis by Interleukin-22,” Journal of Hepatology 53 (2010): 339–347.

[33] P. Kagan, M. Sultan, I. Tachlytski, et al., “Both MAPK and STAT3 Signal Transduction Pathways Are Necessary for Il-6-Dependent Hepatic Stellate Cells Activation,” PLoS ONE 12 (2017): e0176173.

[34] H. K. Min, F. Mirshahi, A. Verdianelli, et al., “Activation of the GP130-STAT3 Axis and Its Potential Implications in Nonalcoholic Fatty Liver Disease,” American Journal of Physiology-Gastrointestinal and Liver Physiology 308 (2015): G794–G803.

[35] Y. Wan, S. Jiang, L. H. Lian, et al., “Betulinic Acid and Betulin Ameliorate Acute Ethanol-Induced Fatty Liver via TLR4 and STAT3 in Vivo and in Vitro,” International Immunopharmacology 17 (2013): 184–190.

[36] B. Gao, “Cytokines, Stats and Liver Disease,” Cellular & Molecular Immunology 2 (2005): 92–100.

[37] W. S. Zhang, A. Pan, X. Zhang, et al., “Inactivation of NF-κB2 (p52) Restrains Hepatic Glucagon Response via Preserving PDE4B Induction,” Nature Communications 10, no. 1 (2019): 4303.

[38] P. Wang, H. Yang, W. Lin, et al., “Discovery of Novel Sesquiterpene Lactone Derivatives as Potent PKM2 Activators for the Treatment of Ulcerative Colitis,” Journal of Medicinal Chemistry 66, no. 8 (2023): 5500–5523.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.